LANSING, Mich., May 4, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) is pleased to announce that Dr. Malcolm Fraser, working in cooperation with Dr. Wang, Dr. Sohn and other members of the scientific team have recently succeeded in building eight unique DNA constructs which the team is preparing for genetic insertion over the next several weeks. These genetic insertion packets include several that are specifically targeted for the production of new fusion silk proteins.
“These constructs include a number of new DNA combinations that are truly exciting,” said CEO Kim K. Thompson. “The increases in laboratory productivity over the last eight months are now enabling us to do more and to do it faster. This number of unique genetic constructs is a new breakthrough for the Company. Each of these constructs has the potential to result in the development of a new polymer or high performance fiber.” The genetic constructs are customized packets of DNA which provide genetic instructions for the creation of new polymers and spider silk based proteins.
Over the last year, the University of Notre Dame added of Dr. Wang, Dr. Sohn and other scientists to the research team. “Since that time we have seen a dramatic increase in both the quality and quantity of the work performed,” said Thompson. “We are ready to ramp up our effort to insert as many constructs as possible,” added Dr. Fraser.
Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.
For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com
This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.
CONTACT: Kraig Biocraft Laboratories, Inc.
Kim K. Thompson, CEO
(517) 336-0807
info@KraigLabs.com